Moving Toward a Cure for Myeloma

Area of Science:

• Hematology
• Oncology
• Immunotherapy

Background:

• Multiple myeloma was historically considered incurable due to frequent relapses.
• Recent therapeutic advancements have led to prolonged remissions and improved patient survival.

Purpose of the Study:

• To review the evolving treatment landscape of multiple myeloma.
• To highlight the impact of novel diagnostics and immunotherapies on achieving deeper responses and challenging the incurable status of the disease.

Main Methods:

• Review of recent therapeutic strategies including induction regimens, high-dose melphalan with autologous stem cell transplantation, and maintenance therapies.
• Discussion of advancements in diagnostic techniques like next-generation sequencing and next-generation flow cytometry for measurable residual disease detection.
• Exploration of emerging immunotherapy approaches, including cellular therapies.

Main Results:

• Modern treatments yield deeper, durable responses with less frequent recurrences.
• Highly sensitive diagnostics (NGS, NGFS) can detect minimal residual disease at 10^-5 to 10^-6 levels.
• Immunotherapies, including cellular therapies, enhance the ability to achieve and maintain measurable residual disease negativity, even in refractory cases.

Conclusions:

• Therapeutic and diagnostic progress is making a cure for multiple myeloma more achievable.
• These advances are shifting the paradigm, challenging the long-held belief that multiple myeloma is an incurable disease.